Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Nasdaq futures fall after record Samsung profit fails to calm AI chip worries
- Oil gains after vessel attacks near Strait of Hormuz
- Citi says SpaceX stock has path to $900+ valuation. Here’s how
- Tesla stock target lifted at RBC on potential SpaceX merger
- Short squeezes more likely than widespread selling: Citi
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Incyte (INCY) PT Lowered to $76 at RBC Capital
May 2, 2018 8:30 AM EDTRBC Capital lowered its price target on Incyte (NASDAQ: INCY) to $76.00 (from $77.00) while maintaining a Outperform rating.
Analyst Brian Abrahams commented, "Jakafi continues to perform solidly and we believe provides a strong valuation foundation; while we acknowledge visibility on life cycle plans, later-stage pipeline... More
Incyte (INCY) Misses Q1 EPS by 2c
May 1, 2018 7:08 AM EDTIncyte (NASDAQ: INCY) reported Q1 EPS of ($0.01), $0.02 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $382 million versus the consensus estimate of $390.05 million.
For earnings history and earnings-related data on Incyte (INCY) click here.
... More